Intermediate for preparing midodrine

ABSTRACT

The invention provides a process for the preparation of 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide of the formula 1 by hydrogenolysis of substituted 2-dibenzylamino-N-[2-(2′,5′-dimethoxyphenyl)-2-hydroxy-ethyl]acetamide having the formula (5), wherein Ar and Ar′ are aryl groups.

This application is a division of and incorporates by reference U.S. patent application Ser. No. 10/040,385, filed Jan. 9, 2002, now U.S. Pat. No. 6,444,851, and Israeli application No. 141,655 filed Feb. 26, 2001.

The present invention is related to a novel process for the preparation of 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride, also known as Midodrine hydrochloride, having the following formula (1).

BACKGROUND OF THE INVENTION

Midodrine is classified as an antihypotensive drug. It was first described and claimed in the U.S. Pat. No. 3,340,298 The drug is dispensed in tablet form as the hydrochloride salt having the structure (1).

The key intermediate required for preparing Midodrine is 1-(2,5-dimethoxyphenyl)-2-aminoethanol hydrochloride having the structure (2).

The synthesis of Midodrine HCl consists of reacting the key intermediate (2) with chloroacetyl chloride to afford 2-chloro-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide (3). The reaction of (3) with sodium azide will provide 2-azido-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide (4) which is subsequently subjected to hydrogenation to afford Midodrine base (6).

Acidification with aqueous HCl will provide Midodrine HCl (1). The above sequence of reactions are outlined in the following scheme (see for example Austrian patent AT 336584).

A serious drawback in the above synthesis of Midodrine HCl involves the use of the dangerously explosive sodium azide. In addition, the above synthesis will involve the formation of the organic azide (4), which is also a potentially explosive material. Both sodium azide and the azide (4) are also toxic materials.

The development of a process for Midodrine HCl, which avoids the use of the highly toxic and explosive sodium azide, will be of great benefit.

SUMMARY OF THE INVENTION

According to the present invention, a process is now available for the preparation of Midodrine hydrochloride (1) via a safe process. In addition, all of the intermediates involved in the preparation of (1) are safe to handle. In the present invention, the toxic and potentially explosive sodium azide is replaced by a safe to handle bis (substituted) diaryl amine, preferably dibenzylamine. The new synthesis of Midodrine HCl consists of reacting 1-(2,5-dimethoxy-phenyl)-2-aminoethanol hydrochloride (2) with chloroacetyl chloride in a mixture of methylene chloride and aqueous potassium hydroxide solution at 5°-10° C. to produce 2-chloro-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]-acetamide (3).

The chloro acetamide derivative (3) is not isolated but reacted in situ, after removal of the methylene chloride, with a bis (substituted) diarylamine having formula (6) in refluxing toluene for a period of about 10 hours. Ar and Ar′ groups in formula (6) are independently phenyl or substituted phenyl groups. The substituents can be chosen from C₁-C₄ alkyl groups, C₁-C₄ alkoxy groups, C₁-C₄ dialkylamino groups and halo groups. The preferred amine of formula (6) is dibenzyl amine of formula (8) wherein both Ar and Ar′ groups are phenyl groups The product, 2-(substituted)-dibenzylamino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide (5) is isolated by filtration. In the next step, the intermediate (5) is hydrogenolyzed to give Midodrine free base (9). The hydrogenolysis is performed at 40°-70° C., preferably 50° C., and 4-6 bar hydrogen pressure using 5% Pd/C as catalyst. The reaction is performed in an alcoholic medium, preferably ethanol. After removal of the alcohol, the Midodrine base (9) is isolated by filtration.

In the final step, the Midodrine base (9) is dissolved in ethanol. The addition of a solution of HCl gas in isopropanol causes the hydrochloride salt of Midodrine to separate from solution. A filtration will afford Midodrine HCl (1) in a highly pure form.

It should be pointed out that all of the reagents as well as the intermediates involved in the process can be safely handled and provide no safety risks. The above sequence of reactions is outlined in the following scheme.

While the invention will now be described in connection with certain preferred embodiments in the following examples so that aspects thereof may be more fully understood and appreciated, it is not intended to limit the invention to these particular embodiments. On the contrary, it is intended to cover all alternatives, modifications and equivalents as may be included within the scope of the invention as defined by the appended claims. Thus, the following examples which include preferred embodiments will serve to illustrate the practice of this invention, it being understood that the particulars shown are by way of example and for purposes of illustrative discussion of preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of formulation procedures as well as of the principles and conceptual aspects of the invention.

EXAMPLES Example 1

Preparation of 2-chloro-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide

The reaction vessel is charged with 15.5 g 1-(2,5-dimethoxyphenyl)-2-amino-ethanol hydrochloride, 115 ml methylene chloride and 100 ml water. The mixture is stirred at 25°-30° C. to afford a clear two-phase mixture. The mixture is cooled to 5°-10° C. and a solution of 18.7 g of 50% potassium hydroxide and 18.5 ml water is added in portions at 5°-10° C.

The mixture is stirred at 5°-10° C. for 15 min. 8.0 ml of chloroacetyl chloride is added in portions at 5°-10° C. causing an exothermic reaction to occur. On completion of the addition, the pH should be adjusted to 3-6. The mixture is allowed to warm to 25°-30° C. and the pH is adjusted again to 3-6. After stirring for one hour at 25°-30° C., the pH is adjusted to 6-7 with 5% aqueous potassium hydroxide solution. The stirring is stopped and the layers are separated.

The upper aqueous layer is washed with 25 ml of methylene chloride. The organic layers are combined and dried over magnesium sulfate. The solution of 2-chloro-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide in methylene chloride is used as is in the next step.

Example 2

Preparation of 2-dibenzylamino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide

The reaction vessel is charged with the methylene chloride solution of 2-chloro-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide prepared in example 1. The majority of the methylene chloride is distilled off at atmospheric pressure. On completion of the distillation 155 ml toluene are added. The mixture is stirred to obtain a solution. 45 to 50 ml of the toluene is distilled to remove the remainder of methylene chloride. The mixture is cooled to 85°-90° C. and 28.4 g dibenzylamine is added in portions at 85°-90° C. On completion of the addition, the mixture is heated to reflux for a period of 10 hours.

On completion of reaction, the resulting suspension is cooled to 45°-50° C. 110 ml water are added followed by 7.5 g of 50% potassium hydroxide. The mixture is stirred at 25°-30° C. for a period of 2-3 hours during which time the product crystallizes from solution. After cooling to 5°-10° C., the product is filtered to afford 21.7 g of 2-dibenzylamino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide. This represents a 75% yield based on the starting material from example 1. The product is characterized as follows:

m.p.: 110.0-111.1° C.

MS: 434 (M⁺)

¹H-NMR (DMSO-d₆): 7.65 ppm, triplet, J=6 Hz, CH₂—NH, 1H; 7.35-7.26 ppm, multiplet, benzyl aromatic protons, 10H; 7.06-6.81 ppm, multiplet, dimethoxy aromatic protons, 3H; 5.60 ppm, doublet, J=5 Hz, CH—OH, 1H; 4.95 ppm, multiplet, CH—OH, 1H; 3.71 and 3.65 ppm, two singlets, two OCH ₃, 6H; 3.54 ppm, broad singlet, two CH ₂—Ph, 4H; 3.36 ppm, singlet, H ₂O; 3.45 and 3.15 ppm, two multiplets, CH ₂—NH, 2H; 2.93 ppm, broad singlet, CH ₂—N, 2H.

¹³C-NMR (DMSO-d₆): 169.62 ppm, C₁₁; 153.19+149.82 ppm, C₁+C₄; 138.21 ppm, C₁₅/C₂₁; 132.26 ppm, C₆; 128.78 ppm, C₁₆/C₂₀/C₂₂/C₂₆; 128.31 ppm, C₁₇/C₁₉/C₂₃/C₂₅; 127.14 ppm, C₁₈/C₂₄; 112.79+112.25+111.59 ppm, C₂+C₃+C₅; 65.49 ppm, C₉; 57.72 ppm, C₁₃/C₁₄; 56.45 ppm, C₁₂; 55.80+55.18 ppm, C₇+C₈; 44.38 ppm, C₁₀.

Example 3

Preparation of 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide (Midodrine Base)

An autoclave is charged with 15.0 g of 2-dibenzylamino-N-[2-(2,5-dimethoxy-phenyl)-2-hydroxyethyl]acetamide, 200 ml ethanol and 1.5 g of 5% Pd/C catalyst. The system is flushed three times with nitrogen followed by hydrogen. The pressure of hydrogen is adjusted to 4-6 bar. The temperature is adjusted to 45°-50° C. The mixture is stirred and heated at 45°-50° C. for 24 hours.

On reaction completion, the mixture is cooled to 25°-30° C. and filtered through a Celite pad to separate the catalyst. The clear f/Uiltrate is transferred to a clean reaction vessel. About ½ of the ethanol is distilled out at atmospheric pressure. On cooling and seeding, Midodrine base will crystallize from solution. After cooling to 5°-10° C., the product is filtered to afford 6.3 g (71% yield) of white Midodrine base. The product is characterized as follows:

m.p.: 105.8°-106.8° C.

MS: 254 (M⁺)

¹H-NMR (DMSO-d₆): 7.88 ppm, triplet, J=6 HZ, CH₂—NH, 1H; 7.02-6.76 ppm, multiplet, aromatic protons, 3H; 5.42 ppm: broad singlet, CH—OH, 1H; 4.90 ppm, multiplet, CH—OH, 1H; 3.73+3.70 ppm, two singlets, two OCH ₃, 6H; 3.45+3.01 ppm, two multiplets, CH ₂—NH, 2H; 3.06 ppm, broad singlet, CH ₂—NH₂, 2H.

¹³C-NMR (DMSO-d₆): 172.75 ppm, C₁₁; 153.11+149.65 ppm, C₁+C₄; 132.45 ppm, C₆; 112.53+112.17+111.48 ppm, C₂+C₃+C₅; 65.64 ppm, C₉; 55.74+55.18 ppm, C₇+C₈; 44.82+44.54 ppm, C₁₀+C₁₂.

Example 4

Conversion of Midodrine Base to Midodrine Hydrochloride

The reaction vessel is charged with 5.0 g Midodrine base and 60 ml ethanol. The mixture is heated to reflux to obtain a clear solution. To the hot mixture is added 6.3 ml of a 22% solution of hydrochloric acid in isopropanol in portions. During the addition, the Midodrine HCl will crystallize from solution. After cooling to 5°-10° C., the product is filtered to afford 4.8 g (96% yield) of Midodrine HCl (m.p.: 200.8°-201.8° C.).

It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative examples and that the present invention may be embodied in other specific forms without departing from the essential attributes thereof, and it is therefore desired that the present embodiments and examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein 

What is claimed is:
 1. 2-dibenzylamino-N-[2-(2′,5′-dimethoxyphenyl)-2-hydroxyethyl]-acetamide having the formula (7) 